<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    jtr
   </journal-id>
   <journal-title-group>
    <journal-title>
     Journal of Tuberculosis Research
    </journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2329-843X
   </issn>
   <issn publication-format="print">
    2329-8448
   </issn>
   <publisher>
    <publisher-name>
     Scientific Research Publishing
    </publisher-name>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="doi">
    10.4236/jtr.2024.124017
   </article-id>
   <article-id pub-id-type="publisher-id">
    jtr-138075
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Articles
     </subject>
    </subj-group>
    <subj-group subj-group-type="Discipline-v2">
     <subject>
      Biomedical 
     </subject>
     <subject>
       Life Sciences, Medicine 
     </subject>
     <subject>
       Healthcare
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    Severe Cor Pulmonale Consequence of Pulmonary Tuberculosis Sequelae: A Case Report 
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Innocent Murhula
      </surname>
      <given-names>
       Kashongwe
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff1"> 
      <sup>1</sup>
     </xref> 
     <xref ref-type="aff" rid="aff2"> 
      <sup>2</sup>
     </xref> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Benoit Obel
      </surname>
      <given-names>
       Kabengele
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff1"> 
      <sup>1</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Armand Patrick
      </surname>
      <given-names>
       Okamba
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff4"> 
      <sup>4</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Grace Mamona
      </surname>
      <given-names>
       Ntima
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff4"> 
      <sup>4</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Aldin Mayimvuanga
      </surname>
      <given-names>
       Kusompi
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff1"> 
      <sup>1</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Eulethere Vita
      </surname>
      <given-names>
       Kintoki
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff4"> 
      <sup>4</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Zacharie Munogolo
      </surname>
      <given-names>
       Kashongwe
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff1"> 
      <sup>1</sup>
     </xref> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
   </contrib-group> 
   <aff id="aff1">
    <addr-line>
     aPulmonology Unit, Internal Medicine Department, Kinshasa University Hospital, Kinshasa, Democratic Republic of Congo
    </addr-line> 
   </aff> 
   <aff id="aff2">
    <addr-line>
     aDrug Resistant Tuberculosis Unit “Centre d’Excellence Damien”, Damian Action, Kinshasa, Democratic Republic of Congo
    </addr-line> 
   </aff> 
   <aff id="aff3">
    <addr-line>
     aNational TB Program of The Democratic Republic of Congo, Kinshasa, Democratic Republic of Congo
    </addr-line> 
   </aff> 
   <aff id="aff4">
    <addr-line>
     aCardiology Unit, Internal Medicine Department, Kinshasa University Hospital, Kinshasa, Democratic Republic of Congo
    </addr-line> 
   </aff> 
   <pub-date pub-type="epub">
    <day>
     30
    </day> 
    <month>
     10
    </month>
    <year>
     2024
    </year>
   </pub-date> 
   <volume>
    12
   </volume> 
   <issue>
    04
   </issue>
   <fpage>
    232
   </fpage>
   <lpage>
    239
   </lpage>
   <history>
    <date date-type="received">
     <day>
      6,
     </day>
     <month>
      November
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="published">
     <day>
      8,
     </day>
     <month>
      November
     </month>
     <year>
      2024
     </year> 
    </date> 
    <date date-type="accepted">
     <day>
      8,
     </day>
     <month>
      December
     </month>
     <year>
      2024
     </year> 
    </date>
   </history>
   <permissions>
    <copyright-statement>
     © Copyright 2014 by authors and Scientific Research Publishing Inc. 
    </copyright-statement>
    <copyright-year>
     2014
    </copyright-year>
    <license>
     <license-p>
      This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/
     </license-p>
    </license>
   </permissions>
   <abstract>
    This case report presents a 63-year-old male patient with a history of TB 20 years prior, who developed chronic cor pulmonale, right heart failure, and eventually died. The report emphasizes the serious long-term effects of post-TB sequelae, highlighting diagnostic challenges, clinical progression, and management strategies. The case report addresses a significant and often overlooked aspect of TB management: the long-term complications following TB treatment, known as post-TB sequelae.
   </abstract>
   <kwd-group> 
    <kwd>
     Post-Tuberculosis Sequelae
    </kwd> 
    <kwd>
      Cor Pulmonale
    </kwd> 
    <kwd>
      Case Report
    </kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <sec id="s1">
   <title>1. Introduction</title>
   <p>Post-tuberculosis sequelae (PTLD) constitute a challenge to the End TB strategy <xref ref-type="bibr" rid="scirp.138075-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.138075-2">
     [2]
    </xref>. The End TB Strategy is a global health initiative launched by the World Health Organization (WHO) in 2014. The strategy aims to end the global tuberculosis (TB) epidemic by 2035. However, PTLD constitutes a challenge and has for a long time not been taken into account as a health problem by the various National tuberculosis programs. The PTLD refers to the evidence of chronic respiratory abnormality, with or without symptoms, attributable at last in part to previous tuberculosis <xref ref-type="bibr" rid="scirp.138075-2">
     [2]
    </xref>-<xref ref-type="bibr" rid="scirp.138075-6">
     [6]
    </xref>. Many patients will need treatment for many symptoms several years after TB is declared cured. One of the End TB strategy goals is to eliminate catastrophic coasts related to TB (1). This will not be reached in presence of PTLD involving more use of health care services and a low quality of life <xref ref-type="bibr" rid="scirp.138075-7">
     [7]
    </xref> <xref ref-type="bibr" rid="scirp.138075-8">
     [8]
    </xref>.</p>
   <p>In the low-income countries, like Democratic Republic of Congo (DRC), TB patients experience a long delay to diagnosis and treatment with increase the risk of having pulmonary tuberculosis sequelea after being cured for tuberculosis desease <xref ref-type="bibr" rid="scirp.138075-9">
     [9]
    </xref>.</p>
   <p>In 2021, the reported incidence was about 254/100.000 less than 300/100.000 projected by WHO <xref ref-type="bibr" rid="scirp.138075-10">
     [10]
    </xref>. So many patients were not diagnosed or experienced a delay in their management. This represents a risk for TB sequelae and their consequences <xref ref-type="bibr" rid="scirp.138075-2">
     [2]
    </xref> <xref ref-type="bibr" rid="scirp.138075-7">
     [7]
    </xref> <xref ref-type="bibr" rid="scirp.138075-11">
     [11]
    </xref>.</p>
   <p>We present a case of chronic cor pulmonale consecutive to lung damage after pulmonary TB treated 20 years ago.</p>
  </sec><sec id="s2">
   <title>2. Case Report</title>
   <p>We present a case of chronic cor pulmonale, which belongs to the structural complications of PTLD, consecutive to lung damage after pulmonary TB treated 20 years ago. He is 63 year-old man with a history of pulmonary TB twenty years ago, presented with gradual increasing dyspnea, non-productive cough and low legs edema. There was no history of smoking. He works as a civil servant. We did not find any exposure to fumes or toxic gases. The main physical examination findings were:</p>
   <p>Good general state, blood pressure: 101/52 mmHg, Oxygen saturation (SaO<sub>2</sub>): 94%, Respiratory rate: 28/minute; pulse rate: 82 /minute.</p>
   <p>We found Jugular vena dilated, Crackles in the two lungs fields and Low legs edema.</p>
   <p>Chest X-ray (<xref ref-type="fig" rid="fig1">
     Figure 1
    </xref>).</p>
   <fig id="fig1" position="float">
    <label>Figure 1</label>
    <caption>
     <title>Figure 1. Chest X-ray bilateral alveolar and interstitial shadows with volume loss and retraction of the right lung, calcified nodules on the left lung and gagged trachea.</title>
    </caption>
    <graphic mimetype="image" position="float" xlink:type="simple" xlink:href="https://html.scirp.org/file/1130561-rId16.jpeg?20241211020956" />
   </fig>
   <p>Chest X-ray: bilateral alveolar interstitial shadows with volume loss and retraction of the right lung, calcified nodules in the left lung and gagged trachea.</p>
   <p>Electro-cardiogram (<xref ref-type="fig" rid="fig2">
     Figure 2
    </xref>)</p>
   <p>Sinus arrhythmia, premature atrial contraction, T abnormality (flat T), Q abnormality (anterior), right ventricular hypertrophy and incomplete right bundle branch.</p>
   <p>Echocardiography (<xref ref-type="fig" rid="fig3">
     Figure 3
    </xref> and <xref ref-type="fig" rid="fig4">
     Figure 4
    </xref>)</p>
   <p>Right cavities (ventricular and atrium) enlargement, thrombus in the right ventricular, pulmonary arterial pressure (PAP): 24 mmHg, inferior vena cava dilated.</p>
   <p>Laboratory investigations</p>
   <p>ESR (erythrocyte sedimentation rate): 11 mm/1sth; Red blood cells: 4.800.000/mm<sup>3</sup>.</p>
   <p>Leukocyte count: 4400/mm<sup>3</sup> with normal differential count.</p>
   <p>Direct sputum smear (Ziehl-Neelson): no acid fast bacilli and Polymerase chain reaction (Gene-xpert) on sputum was negative (no TB mycobacteria detected).</p>
   <fig id="fig2" position="float">
    <label>Figure 2</label>
    <caption>
     <title>Figure 2. ECG.</title>
    </caption>
    <graphic mimetype="image" position="float" xlink:type="simple" xlink:href="https://html.scirp.org/file/1130561-rId17.jpeg?20241211020956" />
   </fig>
   <fig id="fig3" position="float">
    <label>Figure 3</label>
    <caption>
     <title>Figure 3. Echocardiography: dilated right atrium and right ventricle; thrombus in the right ventricle.</title>
    </caption>
    <graphic mimetype="image" position="float" xlink:type="simple" xlink:href="https://html.scirp.org/file/1130561-rId18.jpeg?20241211020956" />
   </fig>
   <fig id="fig4" position="float">
    <label>Figure 4</label>
    <caption>
     <title>Figure 4. Echocardiography: inferior vena cava dilated.</title>
    </caption>
    <graphic mimetype="image" position="float" xlink:type="simple" xlink:href="https://html.scirp.org/file/1130561-rId19.jpeg?20241211020956" />
   </fig>
   <p>Final diagnosis: Chronic Cor Pulmonale with right cardiac failure, severe pulmonary TB sequelae.</p>
   <p>The patient management was mainly symptomatic with diuretic (furosemide), enoxaparine ( 
    <math xmlns="http://www.w3.org/1998/Math/MathML"> <mrow> 
      <msup> 
       <mrow> 
        <mtext>
          lovenox 
        </mtext> 
       </mrow> 
       <mtext>
         R 
       </mtext> 
      </msup> 
     </mrow> 
    </math>), amoxycillin + clavulanic acid. On the third day, he developed uncardiogenic shock refractory to dobutamine treatment and died.</p>
  </sec><sec id="s3">
   <title>3. Discussion</title>
   <p>Post TB sequelae represent a new paradigm for the TB control (2). It remains a global challenge that has long not been taken into account in the various National Tuberculosis Programs (NTP).</p>
   <p>PTLD has been described in 50% - 91% of patients <xref ref-type="bibr" rid="scirp.138075-3">
     [3]
    </xref> <xref ref-type="bibr" rid="scirp.138075-5">
     [5]
    </xref> <xref ref-type="bibr" rid="scirp.138075-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.138075-9">
     [9]
    </xref> <xref ref-type="bibr" rid="scirp.138075-12">
     [12]
    </xref>. Predictive factors are not well defined; some appeared like diagnosis and treatment delay, TB reoccurrence, extensive lung involvement <xref ref-type="bibr" rid="scirp.138075-2">
     [2]
    </xref> <xref ref-type="bibr" rid="scirp.138075-4">
     [4]
    </xref> <xref ref-type="bibr" rid="scirp.138075-5">
     [5]
    </xref> <xref ref-type="bibr" rid="scirp.138075-7">
     [7]
    </xref> <xref ref-type="bibr" rid="scirp.138075-13">
     [13]
    </xref> <xref ref-type="bibr" rid="scirp.138075-14">
     [14]
    </xref>. Genetic background can also interfere in healing process, as some patients develop easily fibrosis <xref ref-type="bibr" rid="scirp.138075-4">
     [4]
    </xref> <xref ref-type="bibr" rid="scirp.138075-5">
     [5]
    </xref> <xref ref-type="bibr" rid="scirp.138075-15">
     [15]
    </xref>.</p>
   <p>Clinical forms of sequelae are very varied <xref ref-type="bibr" rid="scirp.138075-2">
     [2]
    </xref> <xref ref-type="bibr" rid="scirp.138075-3">
     [3]
    </xref> <xref ref-type="bibr" rid="scirp.138075-6">
     [6]
    </xref>-<xref ref-type="bibr" rid="scirp.138075-9">
     [9]
    </xref>.</p>
   <p>Structural complications: bronchiectasis, Tracheobronchial stenosis, broncholithiasis, residual cavitation, lung fibrosis, Tuberculoma, pulmonary bronchial arteritis or thrombosis, bronchial pleural fistula, cor pulmonale, pleural, chest wall and mediastinal involvement.</p>
   <p>Infections complications: aspergillus fumingatus, TB recurrence, non tuberculosis mycobacteria, pneumonia, empyema, chronic obstructive pulmonary disease.</p>
   <p>Psycho-social morbidities: anxiety, depresssion, social isolation, socio economic impairment, catastrophic costs.</p>
   <p>All those damage increase late catastrophic costs <xref ref-type="bibr" rid="scirp.138075-3">
     [3]
    </xref> <xref ref-type="bibr" rid="scirp.138075-12">
     [12]
    </xref> <xref ref-type="bibr" rid="scirp.138075-13">
     [13]
    </xref>.</p>
   <p>Delay to diagnosis and treatment leads to large pulmonary injuries and high risk of sequelae <xref ref-type="bibr" rid="scirp.138075-4">
     [4]
    </xref>-<xref ref-type="bibr" rid="scirp.138075-7">
     [7]
    </xref> <xref ref-type="bibr" rid="scirp.138075-13">
     [13]
    </xref> <xref ref-type="bibr" rid="scirp.138075-16">
     [16]
    </xref>.</p>
   <p>In many cases, pulmonary impairment progress slowly and clinical expression may appear to late between 15 and 20 years after TB treatment <xref ref-type="bibr" rid="scirp.138075-4">
     [4]
    </xref> <xref ref-type="bibr" rid="scirp.138075-12">
     [12]
    </xref>. The case presented experienced TB 20 years ago. This long progression is commonly observed depending with individual factors <xref ref-type="bibr" rid="scirp.138075-4">
     [4]
    </xref> <xref ref-type="bibr" rid="scirp.138075-5">
     [5]
    </xref> <xref ref-type="bibr" rid="scirp.138075-7">
     [7]
    </xref> <xref ref-type="bibr" rid="scirp.138075-8">
     [8]
    </xref>.</p>
   <p>Cor pulmonale, in our case, belong to a chronic respiratory failure state. The extension of lung destruction was probably responsible <xref ref-type="bibr" rid="scirp.138075-17">
     [17]
    </xref> <xref ref-type="bibr" rid="scirp.138075-18">
     [18]
    </xref>.</p>
   <p>The management of TB sequelae mainly depends on clinical profile <xref ref-type="bibr" rid="scirp.138075-12">
     [12]
    </xref>-<xref ref-type="bibr" rid="scirp.138075-14">
     [14]
    </xref>.</p>
   <p>We currently have no codified data or validated recommendations regarding the treatment to be offered to patients with PTLD.</p>
   <p>In the event of post-tuberculosis exacerbation, after excluding a relapse of tuberculosis, the most common causes are: bacterial or viral superinfections, aspergilloma, thromboembolic and cardiovascular complications as well as respiratory failure <xref ref-type="bibr" rid="scirp.138075-7">
     [7]
    </xref> <xref ref-type="bibr" rid="scirp.138075-8">
     [8]
    </xref>.</p>
   <p>Therapeutic program of PTLD must comprise drugs, respiratory rehabilitation, psychosocial and nutritional support. According to the clinical context, broncho-dilatators (beta-agonists with long action, theophyllins, diuretics, gluco-corticoides) can be used. Respiratory failure needs oxygen, COPD exacerbation with infection will receive antibiotics. In some cases, surgery will be discussed.</p>
   <p>There are several proposals for the management of the after-effects of debilitating chronic lung diseases. The management guide provided by the Société de Pneumologie de Langue Française (SPLF) gives interesting suggestions which can also be used for monitoring post-tuberculosis sequelae <xref ref-type="bibr" rid="scirp.138075-19">
     [19]
    </xref>-<xref ref-type="bibr" rid="scirp.138075-23">
     [23]
    </xref>.</p>
   <p>The minimum assessment for any patient who has completed tuberculosis treatment should be biological (hemogram), bacteriological (ziehl, culture), functional (spirometry, 6-minute walk test, respiratory gas analysis) and chest imaging (chest x-ray, optional chest scanner); cardiac assessment would be offered in the event of cardiovascular signs occurring (cardiac ultrasound) looking for pulmonary arterial hypertension and/or chronic cor pulmonale <xref ref-type="bibr" rid="scirp.138075-19">
     [19]
    </xref>.</p>
   <p>The proposed duration of PTLD clinical-radiological monitoring varies depending on patient complaints <xref ref-type="bibr" rid="scirp.138075-20">
     [20]
    </xref>.</p>
   <p>In a patient, with persistent dyspnea for 12 weeks, without obvious etiology at the end of the respiratory functional assessment proposed by the SPLF, it is proposed to look for anemia, thromboembolic disease, a cardiac cause, deconditioning, a syndrome of hyperventilation and diaphragmatic pathology. The guide also recommends a chest CT scan and pulmonary function tests <xref ref-type="bibr" rid="scirp.138075-19">
     [19]
    </xref>.</p>
   <p>If the dyspnea is persistent and the causes so high have been excluded, it is suggested to carry out an exercise test with measurement of the VO2max which allows a multifactorial diagnosis and provides clues, especially in subjects previously in good physical condition, on a single or multifactorial cause of shortness of breath <xref ref-type="bibr" rid="scirp.138075-19">
     [19]
    </xref>.</p>
   <p>Respiratory rehabilitation should be offered to patients who remain symptomatic after specialized respiratory assessment, regardless of spirometric and CT data. It allows a rapid improvement in the quality of life of patients. Little data is available on post-TB respiratory rehabilitation.</p>
   <p>The use of oxygen therapy must follow validated recommendations for chronic pulmonary pathologies.</p>
   <p>It is therefore important that guides specific to thePTLD are developed for optimal care of patients.</p>
   <p>In the Democratic Republic of Congo, in the latest tuberculosis management guide (PATI6) published in 2024, some measures were taken <xref ref-type="bibr" rid="scirp.138075-23">
     [23]
    </xref>:</p>
   <p>- any patient who completes tuberculosis treatment must be evaluated for after-effects by imaging and respiratory function tests.</p>
   <p>- patients with evidence of PTLD must be evaluated for respiratory rehabilitation and referred to the rehabilitation center.</p>
   <p>As a preventive action, traditional TB control activities (prevention, diagnosis and treatment) need to be fine-turned, and wherever possible to diagnose and manage it as early as possible.</p>
  </sec><sec id="s4">
   <title>4. Conclusion</title>
   <p>TB remains a chronic disease. It is associated with frequent pulmonary damage despite microbiological cure. The fight against tuberculosis should no longer be limited to the prevention and treatment of active tuberculosis cases. PTLD must also be taken into account to reduce its impact and decrease his morbi mortality.</p>
  </sec><sec id="s5">
   <title>Authors Contribution</title>
   <p>I.M. Kashongwe: followed the patient and prepared the manuscript.</p>
   <p>A.M. Kusompi: followed the patient.</p>
   <p>A.P. Okamba: cardiac investigations.</p>
   <p>G.M. Ntima: cardiac investigations.</p>
   <p>E.V. Kintoki: cardiac investigations.</p>
   <p>Z.M. Kashongwe: followed the patient and supervised manuscript preparation.</p>
   <p>All the authors revised the final manuscript.</p>
  </sec>
 </body><back>
  <ref-list>
   <title>References</title>
   <ref id="scirp.138075-ref1">
    <label>1</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Matteelli, A., Rendon, A., Tiberi, S., Al-Abri, S., Voniatis, C., Carvalho, A.C.C., et al. (2018) Tuberculosis Elimination: Where Are We Now? European Respiratory Review, 27, Article ID: 180035. &gt;https://doi.org/10.1183/16000617.0035-2018
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref2">
    <label>2</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Visca, D., Centis, R., Munoz-Torrico, M. and Pontali, E. (2020) Post-Tuberculosis Sequelae: The Need to Look Beyond Treatment Outcome. The International Journal of Tuberculosis and Lung Disease, 24, 761-762. &gt;https://doi.org/10.5588/ijtld.20.0488
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref3">
    <label>3</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Sotgiu, G., Centis, R. and Migliori, G.B. (2021) Post-Tuberculosis Sequelae and Their Socioeconomic Consequences: Worth Investigating. The Lancet Global Health, 9, e1628-e1629. &gt;https://doi.org/10.1016/s2214-109x(21)00454-x
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref4">
    <label>4</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Martinez-Garcia, M.A., Guan, W., de-la-Rosa, D., Athanazio, R., Oscullo, G., Shi, M., et al. (2023) Post-TB Bronchiectasis: From Pathogenesis to Rehabilitation. The International Journal of Tuberculosis and Lung Disease, 27, 175-181. &gt;https://doi.org/10.5588/ijtld.22.0566
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref5">
    <label>5</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Revendran, J., Patil, K., Nair, G., Uppe, A., Nanda, V., Sawant, S., et al. (2018) Long Term Sequelae of Pulmonary Tuberculosis and the Factors Predicting Its Development: A ClinicoRadiological Study. European Respiratory Journal, 52, PA2746. &gt;https://doi.org/10.1183/13993003.congress-2018.pa2746
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref6">
    <label>6</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Gohar Ali, M., Syed Muhammad, Z., Shahzad, T., Yaseen, A. and Irfan, M. (2018) Post Tuberculosis Sequelae in Patients Treated for Tuberculosis: An Observational Study at a Tertiary Care Center of a High TB Burden Country. European Respiratory Journal, 52, PA2745. &gt;https://doi.org/10.1183/13993003.congress-2018.pa2745
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref7">
    <label>7</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Muñoz-Torrico, M., Cid-Juárez, S., Gochicoa-Rangel, L., Torre-Bouscolet, L., Salazar-Lezama, M.A., Villarreal-Velarde, H., et al. (2020) Functional Impact of Sequelae in Drug-Susceptible and Multidrug-Resistant Tuberculosis. The International Journal of Tuberculosis and Lung Disease, 24, 700-705. &gt;https://doi.org/10.5588/ijtld.19.0809
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref8">
    <label>8</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Hulya, S., Ilknur, N., Karadeniz, G. and Erkan, S. (2022) Clinical Effects of TB Sequelae in Patients with COPD. The International Journal of Tuberculosis and Lung Disease, 26, 363-368. &gt;https://doi.org/10.5588/ijtld.21.0419
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref9">
    <label>9</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Rafeah Khan, R., Malik, N.I. and Razaque, A. (2019) Imaging of Pulmonary Post-Tuberculosis Sequelae. Pakistan Journal of Medical Sciences, 36, 575-582. &gt;https://doi.org/10.12669/pjms.36.icon-suppl.1722
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref10">
    <label>10</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     WHO (2022) Global Tuberculosis Report 2022. Geneva.
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref11">
    <label>11</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Tomono, K. (1998) The Causes of Death of Pulmonary Tuberculosis: Late Sequelae of Pulmonary Tuberculosis. Kekkaku, 73, 751-754.
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref12">
    <label>12</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Allwood, B.W., van der Zalm, M.M., Amaral, A.F.S., Byrne, A., Datta, S., Egere, U., et al. (2020) Post-Tuberculosis Lung Health: Perspectives from the First International Symposium. The International Journal of Tuberculosis and Lung Disease, 24, 820-828. &gt;https://doi.org/10.5588/ijtld.20.0067
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref13">
    <label>13</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Menzies, N.A., Quaife, M., Allowood, B.W., et al. (2021) Lifetime Burden of Disease Care to Incident Tuberculosis Sequelae. The Lancet Global Health, 9, e1679-e1687. 
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref14">
    <label>14</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Ayari, A., Smadhi, H., Mejri, I., Kamoun, H., Greb, D., Akrout, I., et al. (2015). Management of Pulmonary Tuberculosis Sequelae. European Respiratory Journal, 46, PA2762. &gt;https://doi.org/10.1183/13993003.congress-2015.pa2762
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref15">
    <label>15</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Walter, J.B. and Srael, M.S. (1974) Wound Healing in “General Pathology”. 4th Edition, Churchill Livingstone, 103-115.
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref16">
    <label>16</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Crofton, J., Horne, N. and Miller, F. (1999) Clinical Tuberculosis. ELBS Edition, Mc Millan Education LTD, 103.
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref17">
    <label>17</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Weitzenblum, E. and Chaouat, A. (2009) Cor pulmonale. Chronic Respiratory Disease, 6, 177-185. &gt;https://doi.org/10.1177/1479972309104664
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref18">
    <label>18</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     McLaughlin, V.V., Archer, S.L., Badesch, D.B., Barst, R.J., Farber, H.W., Lindner, J.R., et al. (2009) ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Circulation, 119, 2250-2294. &gt;https://doi.org/10.1161/circulationaha.109.192230
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref19">
    <label>19</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Andrejak, C., Cottin, V., Crestani, B., Debieuvre, D., Gonzalez-Bermejo, J., Morelot-Panzini, C., et al. (2021) Guide de prise en charge des séquelles respiratoires post infection à SARS-CoV-2. Propositions de prise en charge élaborées par la Société de Pneumologie de Langue Française. Version du 10 novembre 2020. Revue des Maladies Respiratoires, 38, 114-121. &gt;https://doi.org/10.1016/j.rmr.2020.11.009
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref20">
    <label>20</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Laouini, I., Abid, N., Loukil, M., Mokni, A., Badri, I. and Ghrairi, H. (2021) Profil clinique et radiologique des séquelles de tuberculose thoracique: À propos de 205 cas. Revue des Maladies Respiratoires Actualités, 13, 225. &gt;https://doi.org/10.1016/j.rmra.2020.11.501
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref21">
    <label>21</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Aminata, B.O., Djelo, D.B., Abdoulaye, B.A., Ibrahima, D.A.T., Oury, B.M. and Lantam, S. (2020) Radiological Aspects of Thoracic Tuberculosis Sequellae in Adults at the Pneumophtisiology Department of Ignace Deen National Hospital. Journal Africain d Imagerie Médicale, 12, 100-106.
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref22">
    <label>22</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Cisse, M.F., Dia Kane, Y., Abessolo, I., Mbaye, F.B.R., Thiam, K. and Toure, N.O. (2020) L’évolution et le devenir des patients avec séquelles de tuberculose thoracique. Revue des Maladies Respiratoires Actualités, 12, 168-169. &gt;https://doi.org/10.1016/j.rmra.2019.11.376
    </mixed-citation>
   </ref>
   <ref id="scirp.138075-ref23">
    <label>23</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Ministère de la Santé et Prévention, République Démocratique du Congo (2024) Guide prise en charge de la tuberculose, 6è Edition, Programme national de lutte contre la tuberculose, PATI 6.
    </mixed-citation>
   </ref>
  </ref-list>
 </back>
</article>